NEWS

| Memo Therapeutics AG

Schlieren, Switzerland, and Vilnius, Lithuania – August 11, 2020 – Swiss biotech company Memo Therapeutics AG (MTx), and Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announce a new partnership to develop a fast-track manufacturing path for MTx’s therapeutic COVID-19 antibody candidate.

| Memo Therapeutics AG

Zurich, Switzerland, and Vilnius, Lithuania – June 25, 2020 – Memo Therapeutics AG and Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), have signed a Development and Manufacturing Agreement for a therapeutic antibody.

| Memo Therapeutics AG

Schlieren, Switzerland – 4 June 2020 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a COVID-19 immunotherapy.

| Memo Therapeutics AG

Schlieren, March 18, 2020. Memo Therapeutics AG is deploying its microfluidic technology platform DROPZYLLA®, to create cognate recombinant libraries from COVID-19 patients who overcame infection in a particularly efficient manner (“elite controllers”). In comparison to other technlogies having a capture rate of far below 5%, MTxs libraries comprise at least 80% of a patient’s antibody repertoire. Capturing essentially the whole antibody repertoire is of crucial importance since antibodies with neutralizing activity represent only a minority of the antibodies made by the human immune system.

| Memo Therapeutics AG

Düsseldorf, Germany and Schlieren, Switzerland October 25th, 2019. ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases and Memo Therapeutics AG, a biotechnology company focused on the discovery and development of therapeutic antibodies from cognate paired antibody libraries today announced the establishment of a collaborative partnership to create libraries from APS-1 memory B cells.

| Memo Therapeutics AG

Memo Therapeutics AG announced today that it is entering preclinical development with its first drug candidate an anti-BKV antibody isolated from humans for the treatment of BK virus infection after renal transplantation.

| Memo Therapeutics AG

Basel, Switzerland, Feb 1st, 2019 - This is a major step in the technology development at Memo since we are now able to directly screen antibody repertoire libraries from rare patients or immunized animals for antibodies with the desired functional activity in a single day.

| Memo Therapeutics AG

Basle, Switzerland, June 11, 2018 - Memo Therapeutics AG announces that Dr. Karsten Fischer was appointed as Chief Executive Officer of the company effective June 01, 2018.

| Memo Therapeutics AG

Basel, Switzerland, May 9th 2018 – Memo Therapeutics AG (“MEMO”), an innovator in the field of antibody discovery and human immune repertoire analysis, announced today the closing of a Series A2 financing round of CHF 5.0 million.

| Memo Therapeutics AG

Memo Therapeutics AG made it to the top 100 of Swiss startups for the third time in a row and is within the top 5 biotech companies. See entire list of companies.

| Memo Therapeutics AG

Memo Therapeutics AG was awarded a new CTI grant

| Memo Therapeutics AG

Memo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform

| Memo Therapeutics AG

Memo Therapeutics AG announces completion of a first commercial project validating its proprietary MemoMAB™ antibody technology platform.

| Memo Therapeutics AG

MEMO’s poster introducing the MemoMAB™ technology platform for the banking and screening of human...

| Memo Therapeutics AG

MEMO’s abstract has been accepted for Poster Discussion presentation...

| Memo Therapeutics AG

Memo Therapeutics AG made it to the top 100 of Swiss startups for the second time in a row and is within the top 10 biotech companies.